Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27733564 | 0.98 | MEN1 (0.53) | MEN1KMT2AFLT1FLT4KDR | |
| SCHEMBL6115030 | 0.98 | MEN1 (0.53) | MEN1KMT2AFLT1FLT4KDR | |
| Hydrochloric Acid SCHEMBL5556082 | 0.98 | MEN1 (0.53) | MEN1KMT2AFLT1FLT4KDR | |
| Anthraquinone SCHEMBL28553728 | 0.88 | PTGS2 (0.52) | MEN1KMT2AFLT1FLT4KDR | |
| SCHEMBL29009732 | 0.83 | IDO1 (0.43) | MEN1KMT2ACA2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL28128748 | 0.82 | IDO1 (0.42) | MEN1KMT2ACA2PTGS2PTGS1 | |
| SCHEMBL4618133 | 0.81 | SOS1 (0.54) | MEN1KMT2AFLT1FLT4KDR | |
| SCHEMBL67606 | 0.81 | SOS1 (0.50) | MEN1KMT2AFLT1FLT4KDR | |
| SCHEMBL474108 | 0.80 | APEX1 (0.48) | KMT2AFLT1FLT4KDRSMN1; SMN2 | |
| SCHEMBL29389290 | 0.80 | APEX1 (0.48) | KMT2AFLT1FLT4KDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024221045-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2024-10-31 | — | — | WO | disclosed |
| WO-2004050897-A2 | METHODS FOR PREPARING ANTIGEN MASKED RED BLOOD CELLS HAVING REDUCED HEMOLYSIS BY SERA | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004049914-A2 | METHODS FOR REACTING AN ANTIGEN MASKING COMPOUND WITH RED BLOOD CELLS WITH HIGH EFFICIENCY | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050848-A2 | METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030207247-A1 | Preparation of red blood cells having reduced immunogenicity | CERUS CORPORATION (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003047650-A2 | PREPARATION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | CERUS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1284743-A2 | PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | Cerus Corporation (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020042043-A1 | Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity | STASSINOPOULOS ADONIS (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2001091775-A2 | PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY | CERUS CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-0921817-B1 | PEGYLATION PROCESS | POLYMASC PHARMACEUTICALS PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-0921817-A1 | PEGYLATION PROCESS | PolyMASC Pharmaceuticals plc (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998032466-A1 | PEGYLATION PROCESS | POLYMASC PHARMACEUTICALS PLC (GB) | 1998-07-30 | — | — | WO | disclosed |
| EP-0216028-A2 | Use of anthranilic-acid derivatives as anthelmintic medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207247-A1 | Preparation of red blood cells having reduced immunogenicity | CD47, HLA-C, HLA-B | MEN1 1711/4885KMT2A 3348/4885FLT1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.